Low-level occupational exposure to crystalline silica is associated with increased risk of mortality from respiratory diseases, pulmonary heart disease, lung cancer and ischaemic heart disease, among other complications, a new study has found.
Similar to their role in other cancers, plasma concentrations of lactate dehydrogenase (LDH) and creatinine kinase (CK) are independent predictors of survival and poor prognosis in lung cancer patients, particularly those with adenocarcinoma, a new study reveals.
Pericardial effusion (PCE) is a common adverse side effect following thoracic radiation therapy for locally-advanced nonsmall cell lung cancer (NSCLC), a new study reveals. Additionally, PCE risk is increased by adjuvant chemotherapy.
Smoking cessation may help lower the risk of cancer, according to a recent study involving young survivors of first myocardial infarction (MI) followed-up longitudinally. Moreover, reducing cigarette smoking may be beneficial.
Obstructive sleep apnoea (OSA) is common among patients with primary aldosteronism (PA), and adrenalectomy or medical therapy for PA appears to be associated with marked improvements in the sleep disorder, a study has found.
Intercalating and maintenance gefitinib may improve progression-free survival and overall survival in nonsmall cell lung cancer (NSCLC) patients with unknown epidermal growth factor receptor (EGFR) mutation status, a recent study has shown.
Patients with chronic hypersensitivity pneumonitis (HP) have small airway abnormalities that may be observed partially using ultrasonic pneumography (UPG) and impulse oscillometry (IOS), according to a study. Furthermore, treatment with azathioprine and prednisone results in improvement in lung volumes but not gas exchange.
LUX-Lung 7, a global phase IIb, randomized, open-label trial, demonstrated significant improvements in progression-free survival (PFS), time to treatment failure (TTF) and objective response rate (ORR) with afatinib vs gefitinib as first-line treatment for patients with advanced, EGFR-positive non-small-cell lung cancer (NSCLC). [ELCC 2016, abstract 140PD]
A combination of live-bacterium immunotherapy and standard chemotherapy is safe and effective in patients with malignant pleural mesothelioma (MPM), providing a response rate of nearly 60 percent, according to a recent phase Ib trial. [ELCC 2016, abstract 208O_PR]
Third-generation EGFR tyrosine kinase inhibitors (TKIs) designed to overcome the T790M mutation have been shown to double progression-free survival (PFS) of patients with advanced non-small-cell lung cancer (NSCLC) harbouring activating EGFR mutations, according to reports at the European Lung Cancer Conference (ELCC) 2016 held recently in Geneva, Switzerland.